King's College London, School of Medicine, Diabetes and Nutritional Sciences Division, London SE1 9NH, UK.
J Nutr. 2013 Jul;143(7):1021-7. doi: 10.3945/jn.112.172585. Epub 2013 May 8.
Marine n3 polyunsaturated fatty acids (PUFAs) activate the transcription factor peroxisome proliferator-activated receptor (PPARγ), which modulates the expression of adiponectin. We investigated the interaction of dietary n3 PUFAs with adiponectin gene (ADIPOQ) single nucleotide polymorphism (SNP) genotypes as a determinant of serum adiponectin concentration. The Modulation of Atherosclerosis Risk by Increasing Doses of n3 Fatty Acids study is a parallel design, double-blind, controlled trial. Serum adiponectin was measured in 142 healthy men and 225 women aged 45-70 y randomized to treatment with doses of 0.45, 0.9, and 1.8 g/d 20:5n3 and 22:6n3 (1.51:1), or placebo for 12 mo. The 310 participants who completed the study were genotyped for 5 SNPs at the ADIPOQ locus: -11391 G/A (rs17300539), -11377 C/G (rs266729), -10066 G/A (rs182052), +45 T/G (rs2241766), and +276 G/T (rs1501299). The -11391 A-allele was associated with a higher serum adiponectin concentration at baseline (n = 290; P < 0.001). The interaction between treatment and age as a determinant of adiponectin was significant in participants aged >58 y after the highest dose (n = 92; P = 0.020). The interaction between +45 T/G and treatment and age was a nominally significant determinant of serum adiponectin after adjustment for BMI, gender, and ethnicity (P = 0.029). Individuals homozygous for the +45 T-allele aged >58 y had a 22% increase in serum adiponectin concentration compared with baseline after the highest dose (P-treatment effect = 0.008). If substantiated in a larger sample, a diet high in n3 PUFAs may be recommended for older individuals, especially those of the +45 TT genotype who have reported increased risk of hypoadiponectinemia, type 2 diabetes, and obesity.
海洋 n3 多不饱和脂肪酸 (PUFA) 可激活转录因子过氧化物酶体增殖物激活受体 (PPARγ),后者可调节脂联素的表达。我们研究了膳食 n3 PUFAs 与脂联素基因 (ADIPOQ) 单核苷酸多态性 (SNP) 基因型的相互作用,作为血清脂联素浓度的决定因素。增加剂量的 n3 脂肪酸调节动脉粥样硬化风险研究是一项平行设计、双盲、对照试验。在随机分为接受 0.45、0.9 和 1.8 g/d 20:5n3 和 22:6n3(1.51:1)或安慰剂治疗的 142 名健康男性和 225 名 45-70 岁女性中测量了血清脂联素。完成研究的 310 名参与者在 ADIPOQ 基因座的 5 个 SNP 上进行了基因分型:-11391 G/A(rs17300539)、-11377 C/G(rs266729)、-10066 G/A(rs182052)、+45 T/G(rs2241766)和+276 G/T(rs1501299)。-11391A 等位基因与基线时较高的血清脂联素浓度相关(n = 290;P < 0.001)。在接受最高剂量治疗的>58 岁参与者中,治疗与年龄作为脂联素决定因素之间的相互作用具有统计学意义(n = 92;P = 0.020)。在调整 BMI、性别和种族后,+45 T/G 与治疗和年龄的相互作用是血清脂联素的名义上的决定因素(P = 0.029)。在接受最高剂量治疗后,>58 岁且为+45T 等位基因纯合子的个体血清脂联素浓度较基线增加 22%(P-治疗效应 = 0.008)。如果在更大的样本中得到证实,富含 n3 PUFAs 的饮食可能会推荐给老年人,尤其是那些报告脂联素血症、2 型糖尿病和肥胖风险增加的+45TT 基因型的人。